---
title: "RBC Capital Remains a Buy on Repligen (RGEN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293690671.md"
description: "RBC Capital analyst Dan Leonard maintained a Buy rating on Repligen (RGEN) with a $160 price target. Shares closed at $140.09. The broader market consensus is Strong Buy, with an average target of $165.36, implying 18% upside. Barclays also recently issued a Buy rating with a $160 target."
datetime: "2026-07-24T01:45:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293690671.md)
  - [en](https://longbridge.com/en/news/293690671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293690671.md)
---

# RBC Capital Remains a Buy on Repligen (RGEN)

In a report released on July 22, Dan Leonard from RBC Capital maintained a Buy rating on Repligen, with a price target of $160.00. The company’s shares closed yesterday at $140.09.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Leonard is a 5-star analyst with an average return of 12.9% and a 59.12% success rate. Leonard covers the Healthcare sector, focusing on stocks such as Danaher, Repligen, and Bio-Techne.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Repligen with a $165.36 average price target, implying a 18.04% upside from current levels. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $160.00 price target.

### Related Stocks

- [RGEN.US](https://longbridge.com/en/quote/RGEN.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [DHR.US](https://longbridge.com/en/quote/DHR.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Repligen–BioLife Deal: Market, Integration and Regulatory Risks Threaten Growth Outlook and Shareholder Returns](https://longbridge.com/en/news/294466535.md)
- [Repligen says BioLife deal targets Q4 close pending regulatory, shareholder approvals](https://longbridge.com/en/news/294739855.md)
- [Bessemer Group Inc. Has $229,000 Holdings in Repligen Corporation $RGEN](https://longbridge.com/en/news/293893842.md)
- [GF Securities Reaffirms Their Buy Rating on Yum China Holdings (YUMC)](https://longbridge.com/en/news/294582595.md)
- [Is Repligen (RGEN) Still Undervalued Following Its $1.5b BioLife Deal?](https://longbridge.com/en/news/293625486.md)